PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Hartleben, G. ; Schorpp, K.K. ; Kwon, Y. ; Betz, B. ; Tsokanos, F.-F. ; Dantes, Z.* ; Schäfer, A.* ; Rothenaigner, I. ; Monroy Kuhn, J.M. ; Morigny, P. ; Mehr, L. ; Lin, S. ; Seitz, S. ; Tokarz, J. ; Artati, A. ; Adamski, J. ; Plettenburg, O. ; Lutter, D. ; Irmler, M. ; Beckers, J. ; Reichert, M.* ; Hadian, K. ; Zeigerer, A. ; Herzig, S. ; Berriel Diaz, M.

Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism.

EMBO Mol. Med.:e12461 (2021)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
By accentuating drug efficacy and impeding resistance mechanisms, combinatorial, multi-agent therapies have emerged as key approaches in the treatment of complex diseases, most notably cancer. Using high-throughput drug screens, we uncovered distinct metabolic vulnerabilities and thereby identified drug combinations synergistically causing a starvation-like lethal catabolic response in tumor cells from different cancer entities. Domperidone, a dopamine receptor antagonist, as well as several tricyclic antidepressants (TCAs), including imipramine, induced cancer cell death in combination with the mitochondrial uncoupler niclosamide ethanolamine (NEN) through activation of the integrated stress response pathway and the catabolic CLEAR network. Using transcriptome and metabolome analyses, we characterized a combinatorial response, mainly driven by the transcription factors CHOP and TFE3, which resulted in cell death through enhanced pyrimidine catabolism as well as reduced pyrimidine synthesis. Remarkably, the drug combinations sensitized human organoid cultures to the standard-of-care chemotherapy paclitaxel. Thus, our combinatorial approach could be clinically implemented into established treatment regimen, which would be further facilitated by the advantages of drug repurposing.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
12.137
2.118
3
6
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Cancer Metabolism ; Integrated Stress Response ; Metabolic Vulnerabilities ; Pyrimidine Metabolism ; Tricyclic Antidepressants
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 1757-4676
e-ISSN 1757-4684
Zeitschrift EMBO Molecular Medicine
Quellenangaben Band: , Heft: , Seiten: , Artikelnummer: e12461 Supplement: ,
Verlag Wiley
Verlagsort Chichester
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Cancer (IDC)
Institute of Molecular Toxicology and Pharmacology (TOX)
Institute of Diabetes and Obesity (IDO)
Molekulare Endokrinologie und Metabolismus (MEM)
Institute of Medicinal Chemistry (IMC)
Institute of Experimental Genetics (IEG)
CF Metabolomics & Proteomics (CF-MPC)
POF Topic(s) 90000 - German Center for Diabetes Research
30203 - Molecular Targets and Therapies
30201 - Metabolic Health
30505 - New Technologies for Biomedical Discoveries
Forschungsfeld(er) Helmholtz Diabetes Center
Enabling and Novel Technologies
Genetics and Epidemiology
PSP-Element(e) G-501900-253
G-501900-251
G-505293-001
G-501900-254
G-502500-001
G-502297-001
G-505600-003
G-506300-001
G-502200-001
G-500600-004
A-630710-001
Förderungen Helmholtz Alliance "Aging and Metabolic Programming, AMPro"
German Research Foundation
DOI 10.15252/emmm.202012461
WOS ID WOS:000625463800001
Scopus ID 85101901759
PubMed ID 33665961
Erfassungsdatum 2021-03-15
[➜Korrektur melden]